A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis

AbstractBackgroundTezacaftor/ivacaftor is a new treatment option in many regions for patients aged ≥12 years who are homozygous (F/F) or heterozygous for the F508del-CFTR mutation and a residual function (F/RF) mutation. This Phase 3, 2-part, open-label study evaluated the pharmacokinetics (PK), saf...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of cystic fibrosis 2019-09, Vol.18 (5), p.708-713
Hauptverfasser:	Walker, Seth, Flume, Patrick, McNamara, John, Solomon, Melinda, Chilvers, Mark, Chmiel, James, Harris, R. Scott, Haseltine, Eric, Stiles, David, Li, Chonghua, Ahluwalia, Neil, Zhou, Honghong, Owen, Caroline A, Sawicki, Gregory
Format:	Artikel
Sprache:	eng
Schlagworte:	Cystic fibrosis Ivacaftor Pulmonary/Respiratory Tezacaftor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!